Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture

BACKGROUND: Lymphocyte activation gene 3 (LAG-3) is a promising immune checkpoint therapeutic target being evaluated in clinical trials. We assessed the LAG-3(+) cells distribution, its association with clinical outcomes and immune contexture and its role in the landscape of muscle-invasive bladder...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Han, Zhou, Quan, Wang, Zewei, Zhang, Hongyu, Liu, Zhaopei, Huang, Qiuren, Wang, Jiajun, Chang, Yuan, Bai, Qi, Xia, Yu, Wang, Yiwei, Xu, Le, Dai, Bo, Guo, Jianming, Liu, Li, Zhu, Yu, Xu, Jiejie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295439/
https://www.ncbi.nlm.nih.gov/pubmed/32540859
http://dx.doi.org/10.1136/jitc-2020-000651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295439/
https://www.ncbi.nlm.nih.gov/pubmed/32540859
http://dx.doi.org/10.1136/jitc-2020-000651

Ejemplares similares